Post-acute sequelae of COVID-19 among hospitalized patients in Estonia: Nationwide matched cohort study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
07
2022
accepted:
09
11
2022
entrez:
23
11
2022
pubmed:
24
11
2022
medline:
26
11
2022
Statut:
epublish
Résumé
Post-acute COVID-19 sequelae refers to a variety of health complications involving different organ systems that have been described among individuals after acute phase of illness. Data from unselected population groups with long-time follow up is needed to comprehensively describe the full spectrum of post-acute COVID-19 complications. In this retrospective nationwide cohort study, we used data obtained from electronic health record database. Our primary cohort were adults hospitalized with confirmed COVID-19 and matched (age, sex, Charlson Comorbidity Index) unaffected controls from general population. Individuals included from February 2020 until March 2021 were followed up for 12 months. We estimated risks of all-cause mortality, readmission and incidence of 16 clinical sequelae after acute COVID-19 phase. Using a frailty Cox model, we compared incidences of outcomes in two cohorts. The cohort comprised 3949 patients older than 18 years who were alive 30 days after COVID-19 hospital admission and 15511 controls. Among cases 40.3% developed at least one incident clinical sequelae after the acute phase of SARS-CoV-2 infection, which was two times higher than in general population group. We report substantially higher risk of all-cause mortality (adjusted hazard ratio (aHR) = 2.57 (95%CI 2.23-2.96) and hospital readmission aHR = 1.73 (95%CI 1.58-1.90) among hospitalized COVID-19 patients. We found that the risks for new clinical sequalae were significantly higher in COVID-19 patients than their controls, especially for dementia aHR = 4.50 (95% CI 2.35-8.64), chronic lower respiratory disease aHR = 4.39 (95% CI 3.09-6.22), liver disease aHR 4.20 (95% CI 2.01-8.77) and other (than ischemic) forms of heart diseases aHR = 3.39 (95%CI 2.58-4.44). Our results provide evidence that the post-acute COVID-19 morbidity within the first year after COVID-19 hospitalization is substantial. Risks of all-cause mortality, hospitalisation and majority of clinical sequelae were significantly higher in hospitalized COVID-19 patients than in general population controls and warrant targeted prevention efforts.
Sections du résumé
BACKGROUND
Post-acute COVID-19 sequelae refers to a variety of health complications involving different organ systems that have been described among individuals after acute phase of illness. Data from unselected population groups with long-time follow up is needed to comprehensively describe the full spectrum of post-acute COVID-19 complications.
METHODS
In this retrospective nationwide cohort study, we used data obtained from electronic health record database. Our primary cohort were adults hospitalized with confirmed COVID-19 and matched (age, sex, Charlson Comorbidity Index) unaffected controls from general population. Individuals included from February 2020 until March 2021 were followed up for 12 months. We estimated risks of all-cause mortality, readmission and incidence of 16 clinical sequelae after acute COVID-19 phase. Using a frailty Cox model, we compared incidences of outcomes in two cohorts.
RESULTS
The cohort comprised 3949 patients older than 18 years who were alive 30 days after COVID-19 hospital admission and 15511 controls. Among cases 40.3% developed at least one incident clinical sequelae after the acute phase of SARS-CoV-2 infection, which was two times higher than in general population group. We report substantially higher risk of all-cause mortality (adjusted hazard ratio (aHR) = 2.57 (95%CI 2.23-2.96) and hospital readmission aHR = 1.73 (95%CI 1.58-1.90) among hospitalized COVID-19 patients. We found that the risks for new clinical sequalae were significantly higher in COVID-19 patients than their controls, especially for dementia aHR = 4.50 (95% CI 2.35-8.64), chronic lower respiratory disease aHR = 4.39 (95% CI 3.09-6.22), liver disease aHR 4.20 (95% CI 2.01-8.77) and other (than ischemic) forms of heart diseases aHR = 3.39 (95%CI 2.58-4.44).
CONCLUSION
Our results provide evidence that the post-acute COVID-19 morbidity within the first year after COVID-19 hospitalization is substantial. Risks of all-cause mortality, hospitalisation and majority of clinical sequelae were significantly higher in hospitalized COVID-19 patients than in general population controls and warrant targeted prevention efforts.
Identifiants
pubmed: 36417409
doi: 10.1371/journal.pone.0278057
pii: PONE-D-22-19899
pmc: PMC9683565
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0278057Informations de copyright
Copyright: © 2022 Tisler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Mod Pathol. 2020 Nov;33(11):2156-2168
pubmed: 32879413
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
PLoS Med. 2022 Jan 25;19(1):e1003871
pubmed: 35077449
BMJ. 2020 Jun 15;369:m2377
pubmed: 32540857
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Lancet Respir Med. 2020 Nov;8(11):1071-1073
pubmed: 33058770
Brain Behav Immun. 2022 Jul;103:154-162
pubmed: 35447302
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
BMJ. 2021 Jan 22;372:n136
pubmed: 33483331
BMC Neurol. 2011 Mar 24;11:37
pubmed: 21435231
Annu Rev Public Health. 2016;37:61-81
pubmed: 26667605
Am J Emerg Med. 2022 Jan;51:267-279
pubmed: 34781153
J Clin Epidemiol. 2015 Jan;68(1):44-51
pubmed: 25447352
BMJ. 2021 May 19;373:n1098
pubmed: 34011492
J Thromb Thrombolysis. 2020 Oct;50(3):512-524
pubmed: 32880795
Lancet Infect Dis. 2021 Oct;21(10):1373-1382
pubmed: 33984263
BMJ. 2021 Mar 31;372:n693
pubmed: 33789877
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
JAMA. 2021 Jan 19;325(3):304-306
pubmed: 33315057
N Engl J Med. 2020 Aug 20;383(8):789-790
pubmed: 32530585
Infect Dis (Lond). 2021 Oct;53(10):737-754
pubmed: 34024217
JAMA Netw Open. 2021 May 3;4(5):e2111417
pubmed: 34037731
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555
PLoS Med. 2021 Sep 28;18(9):e1003773
pubmed: 34582441
Respirology. 2010 Apr;15(3):543-50
pubmed: 20337995
Sci Rep. 2017 Aug 22;7(1):9110
pubmed: 28831119
Clin Infect Dis. 2022 Mar 23;74(6):1089-1092
pubmed: 34166484
Nat Rev Microbiol. 2021 Mar;19(3):141-154
pubmed: 33024307
Thorax. 2021 Apr;76(4):402-404
pubmed: 33273023
Sci Rep. 2017 Dec 8;7(1):17275
pubmed: 29222500
PLoS One. 2021 Mar 4;16(3):e0247461
pubmed: 33661992
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265